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Cytogenetically-deﬁned subgroups of acute myeloid leukaemia have distinct biologies, clinical features and outcomes. Evidence
from therapy-related leukaemia suggests that chromosomal abnormalities are also markers of exposure. Our results suggest
that the smoking-associated risk for acute myeloid leukaemia is restricted to the t(8;21)(q22;q22) subgroup. This supports the
hypothesis that distinct cytogenetic subgroups of acute myeloid leukaemia have separate aetiologies.
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In spite of extensive research into the aetiology of acute myeloid
leukaemia (AML) the cause of the majority of cases remains
unknown. Data from therapy-related leukaemia suggest that differ-
ent carcinogens may induce leukaemias, via separate mechanisms,
with distinct chromosomal abnormalities. For example, AML
which develops after treatment with drugs targeting DNA topo-
isomerase II is characterized by the presence of balanced transloca-
tions, especially those involving the MLL gene located on
chromosome 11 at q23 (Andersen et al, 1998). In contrast, unba-
lanced aberrations (e.g. 75, del(5q), 77 and del(7q))
predominate in AML induced by alkylating agents (Pedersen-Bjer-
gaard et al, 1993). Therefore, using cytogenetics to deﬁne subtypes
of AML may help to identify risk factors more readily.
Although leukaemia is not considered one of the major smok-
ing-related cancers, evidence from a number of cohort and case–
control studies does indicate a weak association. Cohorts of British
doctors and US veterans have both shown small but signiﬁcant
increases in the number of ever smokers developing leukaemia
when compared with life-long non-smokers (Doll et al, 1994;
McLaughlin et al, 1995). Similar results have also been obtained
from a number of case–controls studies, including Brownson et
al (1991), Pasqualetti et al (1997) and Kane et al (1999). Overall,
the increased risk appears to be conﬁned to the ‘acute’ and
‘myeloid’ forms of the disease, rather than the ‘lymphoid’ or
‘chronic’ forms. The most recent case–control study reported an
odds ratio (OR) of 1.2 (95% conﬁdence intervals (CI) (1.0, 1.4))
for the risk of developing AML associated with ever smoking (Kane
et al, 1999). The effect was strongest for current smoking (OR=1.4,
95% CI (1.1, 1.8)) and was absent among ex-smokers (OR=0.9,
95% CI (0.7, 1.2)). Furthermore, some studies have reported that
the risk may be conﬁned to certain cytogenetic subgroups (Crane
et al, 1989, 1996; Sandler et al, 1993). However, the results have
been inconsistent, possibly due to the small number of cases in
each cytogenetic subgroup. In this report the analysis presented
by Kane et al (1999) has been extended to estimate the smoking-
associated risk of AML in the ﬁve most frequent cytogenetic
subgroups.
PATIENTS AND METHODS
This study was based on subjects from a case–control study of
acute leukaemia which has been described in detail elsewhere (Kane
et al, 1999). Brieﬂy, the study ascertained adults (16–69 years-old)
diagnosed with acute leukaemia over a 5-year period in parts of the
north and southwest of England. Controls were randomly selected
from persons registered with the same local physician as the case.
Smoking histories were collected during a face-to-face interview
where smoking was deﬁned as at least one cigarette per day for a
minimum of 6 months. Each subject was classiﬁed as a never,
current or past smoker, assuming a 2-year lag period prior to diag-
nosis.
The current analysis has been restricted to patients with a patho-
logically conﬁrmed diagnosis of de novo AML. Diagnostic
cytogenetic data for the cases were collected from regional labora-
tories (Moorman et al, 2001). Each case was classiﬁed, according to
the clonal aberrations observed in the main leukaemic clone, into
one of ﬁve cytogenetic groups: t(15;17)(q22;q12), t(8;21)
(q22;q22), inv(16)(p13q22), del(5q)/75/del(7q)/77 and +8. Cases
harbouring two or more of these abnormalities were placed into
the ﬁrst group in the list. Other abnormalities occurred too infre-
quently to be considered separately and were therefore grouped
together; as were cases where no abnormality was detected.
Odds ratios (OR) and 95% conﬁdence intervals (CI) were esti-
mated using individual logistic regression models, comparing
cases in each cytogenetic subgroup to all controls; adjusting for
age, sex, region and deprivation. Three comparisons were made:
(1) ever versus never smoking; (2) current versus never smoking;
and (3) past versus never smoking. All analyses were performed
using Intercooled Stata 6.0 for Windows (Stata Corporation,
1999).
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Among 600 cases cytogenetics was successful for 472 (79%)
cases, while 24 (4%) cases failed cytogenetics and 104 (17%)
cases were not tested. Overall, cases had a higher percentage of
smokers, both ever and current, compared to the controls but
fewer ex-smokers (Table 1). A raised odds ratio was observed
for ever smoking (OR=1.19) but the risk was conﬁned to current
smokers (OR=1.42) with no effect being seen among the ex-
smokers (OR=0.94) (Table 2). There was some indication of
variation between the cytogenetic subgroups (Tables 1 and 2).
Among 32 cases with t(8;21), 27 (84%) had smoked at some
point during their lives and 25 (78%) were known to be current
smokers. Within the t(8;21) subgroup, ever and current smoking
were associated with a ﬁve- and seven-fold increased risk of
AML (OR=4.77 and 7.07) but no risk was seen among ex-
smokers (OR=0.34). In contrast, only 23 out of 54 (43%)
t(15;17) cases were ever smokers of which half had given up
the habit. Hence within this subgroup the ORs for ever, current
and past smoking were all reduced (OR=0.57, 0.47 and 0.72).
The estimates of risk in the other cytogenetic subgroups were
either very similar to the risk observed in the whole group or
to unity (Table 2).
These ﬁndings are supported by a US-based study who
reported that ever smoking increased the risk of t(8;21) positive
AML (OR=1.71, 95% CI (0.60, 5.13)) while also observing a
reduced OR for the t(15;17) group (OR=0.42, 95% CI (0.17,
1.01)) (Sandler et al, 1993). However, neither result reached statis-
tical signiﬁcance, probably due to the number of cases in each
group: 26 and 19 cases respectively. Sandler et al (1993) also
reported an increased risk for the –7/del(7q) group (OR=7.91,
95% CI (1.04, 166)) which was not observed in this study (data
not shown) and is in contrast to the reduced OR (OR=0.2,
95% CI (0.1, 0.9)) observed by Crane et al (1989). Direct compar-
isons with the two studies by Crane et al (1989), (1996) are
difﬁcult because their reference group consisted of cases where
no abnormality had been detected, as opposed to disease-free
controls. However, their results also hinted at an association
between ever smoking and t(8;21) positive AML (OR=2.3, 95%
CI (0.8, 6.7) (Crane et al, 1989); OR=1.81, 95% CI (0.59, 6.51)
(Crane et al, 1996)), even though both estimates were based on
under 20 cases. Only one Crane study examined the t(15;17)
subgroup and it showed a reduced OR (OR=0.4, 95% CI (0.1,
1.5)) (Crane et al, 1989). A recent Swedish study did not show
any variation in the smoking-associated risk of AML among
different cytogenetic subgroups, however it should be noted that
the study was not large enough to examine the t(15;17) and
t(8;21) subgroups separately (Bjork et al, 2001).
Although these results suggest the smoking-associated risk of de
novo AML varies according to chromosomal abnormality, they
should be interpreted with caution. Independent veriﬁcation is
needed because the number of cases in each subgroup was not large
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Table 2 Odds ratio and 95% conﬁdence intervals for the risk of de novo acute myeloid
leukaemia associated with smoking, stratiﬁed by cytogenetics
Odds ratio (95% Conﬁdence interval)
a
Group Ever smoking Current smoking Past smoking
All cases 1.19 (0.97, 1.45) 1.42 (1.13, 1.78) 0.94 (0.73, 1.21)
Cytogenetics
b 1.20 (0.96, 1.50) 1.51 (1.18, 1.93) 0.86 (0.65, 1.15)
t(15;17) 0.57 (0.32, 1.00) 0.47 (0.23, 0.96) 0.72 (0.35, 1.49)
t(8;21) 4.77 (1.77, 12.85) 7.07 (2.64, 18.93) 0.34 (0.04, 3.05)
inv(16) 0.85 (0.35, 2.03) 0.95 (0.36, 2.48) 0.72 (0.23, 2.29)
5q-/7q-
c 1.52 (0.75, 3.07) 1.59 (0.71, 3.55) 1.49 (0.67, 3.28)
+8 0.71 (0.34, 1.48) 0.90 (0.40, 2.04) 0.49 (0.17, 1.42)
Other 1.16 (0.72, 1.87) 1.52 (0.91, 2.56) 0.83 (0.46, 1.52)
NAD
d 1.40 (1.01, 1.94) 1.83 (1.28, 2.62) 0.95 (0.63, 1.44)
aOdds ratios and 95% conﬁdence intervals were estimated using logistic regression and adjusted for
age, sex, region and deprivation;
bCases with successful cytogenetic analysis;
cDeletion or monosomy
of 5q or 7q;
dNo abnormality detected.
Table 1 The number and percentage of never, ever, current and past smokers among
controls, and de novo acute myeloid leukaemia cases stratiﬁed by cytogenetics
Smoking status, n (%)
a
Group Total Never Ever Current Past
Controls 1593 647 (41) 943 (59) 461 (29) 472 (30)
All cases 600 215 (36) 380 (63) 224 (37) 153 (26)
Cytogenetics
b 472 170 (36) 297 (63) 185 (39) 109 (23)
t(15;17) 54 31 (57) 23 (43) 11 (20) 12 (22)
t(8;21) 32 5 (16) 27 (84) 25 (78) 1 (3)
inv(16) 24 11 (46) 13 (54) 8 (33) 5 (21)
5q-/7q-
c 43 12 (28) 31 (72) 14 (33) 17 (40)
+8 32 16 (50) 15 (47) 10 (31) 5 (16)
Other 85 32 (38) 52 (61) 32 (38) 20 (24)
NAD
d 202 63 (31) 136 (67) 85 (42) 49 (24)
aThe smoking status was unknown for ﬁve cases and three controls, and the current smoking status
was unknown for three cases and 10 controls;
bCases with successful cytogenetic analysis;
cDeletion or
monosomy of 5q or 7q;
dNo abnormality detected.
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other factors such as alcohol or diet for which we have no data.
However, they do support a link between exposure and speciﬁc chro-
mosomal aberrations. The mechanism by which smoking may cause
AML and in particular t(8;21) positive AML is far from clear.
However, tobacco smoke is the largest environmental source of
benzene (Wallace, 1996) which is a well established risk factor for
AML (Rinsky et al, 1987). Further indirect support comes from the
observation that Chinese factory workers exposed to benzene showed
a higher rate of translocations involving chromosomes 8 and 21 than
controls; indeed one worker was shown to harbour the ETO/AML1
fusion gene, the usual molecular consequence of t(8;21) (Smith et
al, 1998). Future aetiological studies investigating AML may prove
more fruitful if they include cytogenetic data and focus the analysis
on subgroups of patients with identical or similar types of chromoso-
mal abnormality.
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